• Annexin V-FITC/7-AAD Apoptosis Kit: Precision in Tumor Cell

  2026-07-17

  Explore the scientific rigor and advanced applications of the Annexin V-FITC/7-AAD Apoptosis Kit in precise cell death analysis and radiotherapy research. This article uniquely connects apoptosis detection with modern radiosensitization strategies, providing guidance for innovative experimental design.

• 2,7-Dichlorodihydrofluorescein Diacetate: Reliable ROS Assay

  2026-07-17

  This article addresses real-world laboratory challenges in oxidative stress and cell viability assays, demonstrating how 2,7-Dichlorodihydrofluorescein diacetate (SKU C3890) offers robust, data-driven solutions. Drawing on peer-reviewed research and best practices, it provides scenario-driven guidance for biomedical researchers and lab technicians seeking reproducible, sensitive ROS detection.

• 3X (DYKDDDDK) Peptide: Pioneering Biofilm and Beyond in Tran

  2026-07-16

  This thought-leadership article dissects the mechanistic, experimental, and strategic frontiers of the 3X (DYKDDDDK) Peptide (3X FLAG peptide) for translational research. Bridging advanced protein tagging, affinity purification, and immunodetection with emerging insights from cyanobacterial biofilm studies, it provides actionable guidance for researchers. By contextualizing APExBIO’s 3X FLAG peptide within evolving workflows and benchmarking it against new biological revelations, this article advances the conversation beyond standard product profiles.

• PLK4-EphA2 Axis Drives Glioma Progression and Vasculogenic M

  2026-07-16

  This study uncovers how Polo-like kinase 4 (PLK4) accelerates glioma malignant progression and vasculogenic mimicry (VM) by directly phosphorylating EphA2 on Ser901 and Ser897. These findings clarify a critical signaling mechanism and offer insights for targeting VM in glioblastoma, which may inform future therapeutic strategies.

• Dacomitinib (PF-00299804): Transforming Pan-HER Cancer Model

  2026-07-15

  Explore how Dacomitinib (PF-00299804) revolutionizes cancer research through irreversible ErbB family inhibition and advanced apoptosis induction. This article uniquely integrates molecular mechanism insights with practical assay optimization strategies for oncology studies.

• ICV CCK-8s Drives Anxiety-like Behavior in Zebrafish via CCK

  2026-07-15

  This study demonstrates that intracerebroventricular administration of two sulfated cholecystokinin octapeptide forms (CCK-8s) induces robust anxiety-like behavior in zebrafish, linked to widespread CCK-like immunoreactivity in the brain. These findings clarify the functional neuroanatomy and receptor-mediated mechanisms underlying CCK-induced behavioral modulation, providing a valuable model for neurobehavioral research.

• Losmapimod (GW856553X): Workflow Optimization in Inflammatio

  2026-07-14

  Losmapimod (GW856553X) stands out as a dual-action, selective p38 MAPK inhibitor, uniquely enabling precise modulation of inflammation and vascular function in both in vitro and in vivo models. This guide distills actionable protocol enhancements, troubleshooting strategies, and mechanistic insights to help researchers maximize reproducibility and data quality in hypertension and COPD research.

• AMG 487: Precision CXCR3 Antagonist for Macrophage Polarizat

  2026-07-14

  AMG 487 enables targeted and reversible modulation of macrophage polarization through potent CXCR3 inhibition, offering exceptional resolution for dissecting inflammatory versus non-inflammatory signaling. Its robust performance in both cell-based and in vivo models positions it as a pivotal tool for researchers studying chemokine-driven inflammation and acute lung injury.

• Plk1 Regulation of p31comet and Mitotic Checkpoint Disassemb

  2026-07-13

  This study uncovers how Polo-like kinase 1 (Plk1) directly regulates the mitotic checkpoint protein p31comet via phosphorylation, controlling the disassembly of the mitotic checkpoint complex (MCC) and precise cell cycle progression. These findings clarify a critical regulatory mechanism that prevents premature checkpoint inactivation and highlight the complexity of mitotic exit control.

• Structure-Based Discovery of NSP15 Inhibitors for SARS-CoV-2

  2026-07-13

  This study uses structure-based virtual screening to identify thymopentin and oleuropein as potent inhibitors of the SARS-CoV-2 NSP15 endoribonuclease. The findings suggest new avenues for antiviral drug development and highlight the utility of computational screening in targeting viral immune evasion.

• Merbromin Selectively Inhibits SARS-CoV-2 3CLpro: Mechanisti

  2026-07-12

  Chen et al. identified Merbromin as a selective, mixed-type inhibitor of the SARS-CoV-2 main protease 3CLpro through high-throughput screening. This study provides mechanistic clarity for antiviral drug development while highlighting the differential specificity of common proteases in molecular biology workflows.

• Cefotaxime: Third-Generation Cephalosporin in AMR Research

  2026-07-10

  Harnessing Cefotaxime’s robust beta-lactamase resistance, researchers can dissect multidrug resistance and bacterial infection models with unprecedented control. This guide delivers actionable workflows, troubleshooting insights, and direct translation of cutting-edge findings to accelerate next-generation antimicrobial resistance research.

• Dual-Action p38α MAPK Inhibitors Accelerate Dephosphorylatio

  2026-07-09

  The reference study uncovers that specific kinase inhibitors can both block p38α MAPK activity and promote its dephosphorylation by the WIP1 phosphatase. This dual-action mechanism, revealed by structural and biochemical analysis, offers a new strategy for designing more potent and selective tools for inflammation and apoptosis research.

• ISRIB Reverses Inflammation-Driven Accelerated Forgetting in

  2026-07-09

  A recent study demonstrates that ISRIB (trans-isomer), a selective PERK inhibitor, can reverse accelerated forgetting of recognition memory induced by systemic inflammation in mice. These findings highlight the integrated stress response as a mechanistic link between neuroinflammation and pathological memory loss, opening new pathways for targeted intervention in neurodegenerative disease models.

• Optimizing Cancer Assays with Dovitinib (TKI-258, CHIR-258)

  2026-07-08

  This article addresses persistent challenges in cancer cell viability and apoptosis assays by presenting scenario-driven solutions leveraging Dovitinib (TKI-258, CHIR-258), SKU A2168. We discuss evidence-based strategies for protocol optimization, data interpretation, and supplier selection, highlighting how Dovitinib’s multitargeted RTK inhibition and high-quality sourcing from APExBIO enhance reproducibility and research confidence.

14708 records 2/981 page Previous Next 12345 下5页 Last page